Completed PHASE3 INTERVENTIONAL 2-arm NCT00640562

Quetiapine Extended Release Depression Symptoms (ExAttitude)

Comparison of Quetiapine Extended-Release (Seroquel XR™) and Risperidone in the Treatment of Depressive Symptoms, in Schizophrenic or Schizoaffective Patients: A Randomized, Open Label, Flexible-dose, Parallel Group, Non Inferiority, 12-week Study

Sponsor: AstraZeneca

Conditions Depression Schizophrenia

Interventions Quetiapine Extended Release Risperidone

Updated 8 times since 2017 Last updated: May 17, 2012 Started: Feb 29, 2008 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00640562, this PHASE3 trial focuses on Depression and Schizophrenia and remains completed. Sponsored by AstraZeneca, it has been updated 8 times since 2008, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aversa, Italy , Bergamo, Italy , Brindisi, Italy , Carbonia, Italy , Catania, Italy , Collegno, Italy , Fermo, Italy , Frattaminore, Italy , La Spezia, Italy , Lecco, Italy and 11 more locations